Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
Seattle, May 28, 2024 - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company focused on breast cancer treatment, has announced its support for a new Phase 2 study aimed at validating an innovative artificial intelligence-driven breast cancer risk assessment model. The study, known as the SMART (Stockholm MAmmography Risk stratified Trial), will utilize an individualized, imaging-based screening model to identify women who are at the highest risk of developing breast cancer within the next two years.
Breast cancer is the most prevalent cancer among women worldwide, and early detection is crucial for improved outcomes. Current screening methods, such as mammography, have limitations, often leading to false positives or negatives. Therefore, the development of a more accurate risk assessment model could significantly impact the field of breast cancer prevention and treatment.
The SMART study aims to leverage artificial intelligence technology to analyze mammography images and identify patterns, markers, and risk factors associated with the development of breast cancer. By utilizing advanced algorithms, the model will enhance risk assessment capabilities, enabling more accurate detection and diagnosis of breast cancer in its early stages.
If the results of the SMART study validate the efficacy and reliability of the artificial intelligence-driven risk assessment model, it could potentially serve as the foundation for a future Phase 3 trial. This future trial would investigate the use of (Z)-endoxifen, a potential therapeutic agent, in breast cancer prevention settings.
(Z)-endoxifen is a key compound being developed by Atossa Therapeutics. It is an active metabolite of tamoxifen, a well-established selective estrogen receptor modulator used for the treatment of hormone receptor-positive breast cancer. The Phase 3 trial would focus on evaluating the ability of (Z)-endoxifen to prevent breast cancer development in high-risk individuals identified by the risk assessment model.
By utilizing artificial intelligence and advanced imaging techniques, Atossa Therapeutics aims to revolutionize breast cancer risk assessment, enabling more effective prevention and treatment strategies. The ultimate goal is to develop personalized therapies that can significantly reduce the global burden of breast cancer.
Dr. Steven C. Quay, CEO and President of Atossa Therapeutics, expressed his excitement regarding the SMART study, stating, We believe that the future of breast cancer prevention lies in individualized, precision medicine. By combining advanced imaging technology with artificial intelligence algorithms, we have the potential to revolutionize breast cancer risk assessment and subsequently develop targeted therapies for prevention. This study marks a significant milestone in our ongoing efforts to combat breast cancer and improve patient outcomes.
In summary, Atossa Therapeutics’ support of the SMART study is a significant step toward revolutionizing breast cancer risk assessment using artificial intelligence. The study aims to validate an individualized, imaging-based screening model that can identify women at the highest risk of developing breast cancer in the near future. The success of the study could pave the way for a Phase 3 trial investigating (Z)-endoxifen as a preventive measure for breast cancer. Atossa Therapeutics is committed to advancing personalized therapies that can transform breast cancer prevention and treatment.
Comments